1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Ciltacabtagene Autoleucel: new trials by email Literature Review of Ciltacabtagene Autoleucel trials Research Report on Ciltacabtagene Autoleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2023-04-19 | 2026-03-12 |
| A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma LCAR-B38M CAR-T Cell - Multiple Myeloma | Phase 2 | Terminated | Nanjing Legend Biotech Co. | 123 | 2019-01-23 | 2025-12-17 |
Multiple Myeloma (3) · Smoldering Multiple Myeloma (1)
Dana-Farber Cancer Institute (1) · Mayo Clinic (1) · Nanjing Legend Biotech Co. (1)
United States (2) · China (1)
Irene Ghobrial, MD (1) · Yi Lin, MD, PhD (1)
P50CA186781 (1)